Compare Novartis AG (NVS) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs T-Mobile Us Inc — how do they compare? Novartis AG trades at $139.6 (market cap $262.64B), while T-Mobile Us Inc trades at $178.02 (market cap $194.89B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | TMUS | |
|---|---|---|
Market Cap | $262.64B | $194.89B |
Sector | Health | Media |
52-Week High | $168.62 | $241.67 |
52-Week Low | $121.80 | $167.65 |
Enterprise Value | $303.97B | $311.51B |
Dividend Yield | 3.44% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement with a 0.09% gain. The stock faces bearish technical signals but maintains strong fundamentals with consistent revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability margins. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company announced a CFO transition effective February 2027 and continues strategic partnerships, including the Paramount+ Plaza naming rights deal announced September 8, 2026.
TMUS presents a compelling long-term opportunity with 80% analyst buy ratings and a $233.20 consensus price target implying 28% upside. However, rising debt levels (debt-to-asset ratio increased to 39.35% in 2025) and competitive broadband pricing pressures pose risks. The stock's valuation at 19x P/E appears reasonable given sector positioning and growth trajectory, though technical weakness suggests near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
